The following criteria is provided for health care professionals.

Inclusion Criteria:

• Patient must be newly diagnosed with multiple myeloma, based on following IMWG 2014 definition (Rajkumar et al 2014):
• Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:
• Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder
• Any one or more of the following biomarkers of malignancy:
  1. Clonal bone marrow plasma cell percentage ≥ 60%
  2. Involved: uninvolved serum free light chain ratio ≥ 100
  3. >1 focal lesions on MRI studies
• Patient must have measurable disease defined by at least 1 of the following conditions present at screening:
• Serum M-protein by Protein Electrophoresis (PEP) ≥ 1.0 g/dL (≥ 10 g/L).
• Urine M-protein by PEP ≥ 200 mg/24 hours. Involved serum free light chain level ≥ 10 mg/dL (≥ 100 mg/L), provided that the serum free light chain ratio is abnormal.
• Patient must be eligible for autologous stem cell transplantation based on the investigator's clinical judgment.
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
• Patient's age is ≥ 18 and <75 years at time of signing the informed consent
• Patient has provided written informed consent prior to any screening procedures
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline

Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

• Any concomitant anti-cancer therapy (other than bortezomib/lenalidomide/dexamethasone; bisphosphonates are permitted only if commenced prior to the start of screening period)
• Unresolved diarrhea ≥ CTCAE grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease).
• Allogeneic stem cell transplant recipient presenting with graft versus host disease either active or requiring immunosuppression
• Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug, following locally applicable prescribing information
• Patient has grade ≥ 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination at screening
• Patient received prior treatment with DAC inhibitors including Panobinostat
• Patient needing valproic acid for any medical condition during the study or within 5 days prior to first administration of panobinostat/study treatment.
• Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted only if commenced prior to the start of screening period)
• Patient who received:
  1. prior anti-myeloma chemotherapy or medication including Immunomodulator (IMiDs) and Dex ≤ 3 weeks prior to start of study.
  2. experimental therapy or biologic immunotherapy including monoclonal antibodies ≤ 4 weeks prior to start of study.
  3. prior radiation therapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior start of study.
• Patient has not recovered from all therapy-related toxicities associated with above listed treatments to < grade 2 CTCAE.
• Patient has undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy to < grade 2 CTCAE
• Patients with evidence of mucosal or internal bleeding
• Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 month prior to screening)
• Inability to determine the Fridericia's Correction Formula (QTc) F interval
• Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat (e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or small bowel resection)
• Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for 6 months after stopping treatment
• Pregnant or nursing (lactating) women.